Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; none of the 91 sources its claims cite is checked for support yet.

Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men

Open access
Van Gerwen, Olivia T, Camino, Andres F, Sharma, Jyoti, Kissinger, Patricia J, Muzny, Christina A · 2021 · Clinical Infectious Diseases

Abstract

Trichomonas vaginalis infections in men are traditionally considered to be benign and consequently have been overlooked. However, men with this common sexually transmitted infection can experience urethritis, prostatitis, reduced fertility, and amplified human immunodeficiency virus risk. In addition, men are often asymptomatic and can unknowingly spread the infection to their female sexual partners. With advances in T. vaginalis diagnostics, more men are being diagnosed, yet the optimal method of treatment in men remains unknown. The purpose of this review is to discuss the epidemiology, natural history, diagnosis, and treatment of T. vaginalis among men.

Overview

CoChat Summary

TL;DR

This review summarizes the epidemiology, natural history, diagnosis, and treatment of *Trichomonas vaginalis* in men, emphasizing that male infections are common, often asymptomatic, and underdiagnosed. It concludes that the optimal treatment regimen in men remains unknown and calls for better natural history and treatment data.

Key findings

  • In 2016, WHO estimated global *T. vaginalis* prevalence at 5.0% in women and 0.6% in men, with male prevalence ranging from 0.2% to 1.3% and highest rates in Africa and the Americas. In the United States, male incidence was estimated at 4.1 million infections in 2018, and NHANES 2013–2014 estimated prevalence in men aged 18–59 years at 0.5% versus 1.8% in women.
  • Up to 72% of male sexual partners of infected women can also be infected. In one US study of 177 men with trichomoniasis-infected female partners, 136 (76.8%) were infected but asymptomatic; among symptomatic men, penile discharge was most commonly reported.
  • NAATs are now the gold standard: Xpert TV assay showed 97.2% sensitivity and 99.9% specificity; Cobas TV/MG assay 100% sensitivity and 98.4% specificity; BDMax CTGCTV2 assay 97.9% sensitivity and 99.7% specificity. Culture sensitivity was 40–56% with 100% specificity, and wet-mount microscopy was 25–40% sensitive and not recommended for men. Penile meatal swabs had 80.4% sensitivity versus 39.3% for urine in one home-testing study, and 85% sensitivity/96.7% specificity versus clinician-collected urethral swabs; 86% of men in one study preferred self-collected penile swabs.
  • Treatment data in men are limited: in a Russian study of 210 men given 2 g metronidazole (MTZ), cure was 57.6%; in a Zimbabwean study, only 42.9% of 38 men given 2 g MTZ cleared infection, whereas all 287 men given 400 mg MTZ three times daily for 5 days cleared infection. In a Japanese study, 1 g tinidazole and 1.5 g MTZ both yielded 100% negative cultures at 14 and 30 days; in an Egyptian study, all 85 men treated with ornidazole, MTZ, or secnidazole tested negative.

Methods

  • Design: narrative review of the epidemiology, natural history, diagnosis, and treatment of *T. vaginalis* in men.
  • Data: published literature, CDC treatment guidelines, and tables summarizing diagnostic tests and treatment studies in men; no primary data were collected.
  • Analysis: qualitative synthesis of existing studies and guidelines; no systematic search strategy or meta-analysis is described.

Limitations

  • Stated in the paper: natural history studies in men are limited and difficult to conduct because men are often asymptomatic; the optimal treatment method in men remains unknown; no data exist on MTZ resistance in men; most trichomoniasis research has been conducted in women; and routine screening is not currently recommended by the CDC.
  • Stated in the paper: current treatment recommendations for men have largely been extrapolated from studies in women, and an adequately powered head-to-head comparison of 2 g MTZ versus multidose MTZ in men is needed.
  • Evident from the text: as a narrative review, it reports no systematic search strategy, inclusion criteria, or formal risk-of-bias assessment, and many cited studies are small, old, or placed in supplementary references.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/cid/ciab514

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 1 Not valid · 69 Not checked · 10 Own results and interpretations

44 more claims

Create a free account to see all 80 claims and to verify the 51 references still open.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 42 references

Cited by

See all 81

Metadata

Authors
Van Gerwen, O. T., Camino, A. F., Sharma, J., Kissinger, P. J., & Muzny, C. A.
Affiliations
  • Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
  • University of Alabama (US)
  • University of Alabama at Birmingham (US)
  • Tulane University (US)
Venue
Clinical Infectious Diseases
Published
2021-07-04
Volume
73
Issue
6
Pages
1119-1124
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3164421300
Cited by
81
References
42
Citations by year
2026: 11 · 2025: 18 · 2024: 24 · 2023: 15 · 2022: 12 · 2021: 1
FWCI
1.15
Type
journal article
Language
en
Open access
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
Funders
  • Agency of Healthcare Research and Quality (T32HS013852)
  • National Center for Advancing Translational Sciences
  • National Institutes of Health (TL1TR003106)
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Urology › Urinary Tract Infections Management
  • Life Sciences › Immunology and Microbiology › Parasitology › Parasitic Infections and Diagnostics
Keywords
Trichomonas vaginalis, trichomoniasis, men, sexually transmitted infections, urethritis, prostatitis, male fertility, HIV risk, asymptomatic infection, epidemiology, natural history (disease), diagnosis, treatment
MeSH terms
Humans, Male, Sexual Partners, Sexually Transmitted Diseases, Trichomonas Infections, Trichomonas vaginalis, Urethritis, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men. https://app.cochat.ai/papers/10.1093/cid/ciab514
The paper
Van Gerwen, O. T., Camino, A. F., Sharma, J., Kissinger, P. J., & Muzny, C. A. (2021). Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab514

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.